title: [Anti-TNFα therapy and its implication in gynecology and obstetrics].
abstract: Anti-TNFα treatments have modified the medical care, the course and the quality of life of the patients with autoimmune rheumatic, cutaneous or bowel inflammatory diseases. On the other hand, these treatments may have potential severe side effects during pregnancy (congenital malformations, fetal infections). Actually, many pregnancies have been reported during anti-TNFα exposures, with good maternal and neonatal outcomes. The introduction or the discontinuation of these treatments will always have to be discussed with the specialist of the chronic disease and, ideally, during a preconceptional counselling. In gynecology, anti-TNFα drugs may offer a new safe and effective approach to treating patients with recurrent miscarriages or unexplained or failed in vitro fertilization cycles. On the other hand, these treatments significantly increase the risk for serious infections or viral reactivations and may promote gynaecological malignancies. An adapted gynaecological survey is necessary.
authors: Service de gynécologie obstétrique, hôpital Beaujon, AP-HP, université Paris 7, 100, boulevard du Général-Leclerc, 92110 Clichy, France. g.ducarme@gmail.com
authors: G
authors: G
authors: Ducarme
authors: P
authors: P
authors: Amate
authors: M
authors: M
authors: Seirafi
authors: P-F
authors: PF
authors: Ceccaldi
authors: Y
authors: Y
authors: Bouhnik
authors: D
authors: D
authors: Luton
mesh_terms: D000893:Anti-Inflammatory Agents / Q000009:adverse effects / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D006176:Gynecology / Q000379:methods*; D006801:Humans; D015212:Inflammatory Bowel Diseases / Q000188:drug therapy; D000069285:Infliximab; D009774:Obstetrics / Q000379:methods*; D011247:Pregnancy; D011248:Pregnancy Complications / Q000188:drug therapy*; D012216:Rheumatic Diseases / Q000188:drug therapy; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors / Q000276:immunology*
chemical_list: D000893:Anti-Inflammatory Agents; D000911:Antibodies, Monoclonal; D014409:Tumor Necrosis Factor-alpha; D000069285:Infliximab